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With the force something like a tsunami wave, a surge
of genome-wide association studies (GWASs) in common
complex diseases has ﬂooded the recent literature and
left us awash with data regarding the identiﬁcation of
causative genetic risk factors for cardiovascular disease such
as hypertension. Nevertheless, the more slowly moving tide
of the classical candidate gene approach also makes steady
progress to clarify the interaction between gene function
and pathogenesis of hypertension. Like most other common
conditions the estimated eﬀects of each genetic variant
on blood pressure and the predisposition to hypertension
is quite small, yet the delineation of genetic contribution
could reveal new targets for risk reduction in cardiovascular
disease.
The main focus of this special issue is to highlight the
genetic basis of hypertension and cardiovascular disease and
outline recent progress in genomics. In addition, several
successful investigations in common diseases are introduced
as good examples of the potential for better understanding of
hypertension using genomic approaches.
In the ﬁrst part of this issue, two papers provide clear
reviews of the recent progress in the GWAS approach for
hypertension and coronary artery disease. These papers
elucidate not only the common ﬁndings in studies that,
to a certain extent, disparate but also interprete these
ﬁndings in the context of the advantages and limitations
of GWAS. This context includes the contrast between the
very strong (genome-wide) signiﬁcance of associations and
the relatively small phenotypic eﬀects of each SNP. In terms
of discovery potential, unexpected candidate genes obtained
from GWAS provide fresh perspectives in hypertension
research.
But the genomic picture is for more complex than
isolated SNPs. It involves the ways in which the sophisticated
organization of the operational elements of the genome
interdigitates to provide tissue and development stage-
speciﬁc regulation and integration of gene expression. It also
aligns these factors with phenotypic changes that can result.
Two subsequent review articles illustrate these principles by
showcasing a new cutting edge of cardiovascular research in
the form of microRNAs (miRNAs) and scavenger receptors.
Both papers disclose the potentials of these newcomers as
therapeutic targets of cardiovascular disease.
In a more focused review of candidate genes, the
next 2 papers focus on gene polymorphisms of adrenergic
receptors. K. Masuo examines the critical role of beta2- and
beta3-adrenoceptors gene polymorphisms on hypertension
or metabolic syndrome unequivocally. K. B. Bostr¨ om et
al. report that a polymorphism (Arg389Gly) of beta1-
adrenoceptor gene is signiﬁcantly associated with increased
risk of obstructive sleep apnea (OSA) with hypertension.
In the research using candidate gene approach, precise
and appropriate phenotyping is important to identify small
but signiﬁcant genetic eﬀect. G. D. Kitsios and E. Zintzaras
reveal the protective eﬀectofahaplotypeofendothelialnitric
oxide synthase gene (NOS3) for predisposition to hyperten-
sion.K.Sugimotoetal.pointoutthatapolymorphisminthe
promoterregionofregulatorofGproteinsignaling-2(RGS2)
gene aﬀects the diﬀerence of antihypertensive medication in
a clinical trial.
Thelasttwopapersextendtheconsiderationofnoveland
unexpected concepts for cardiovascular research. A recent
topic is the awareness of shared physiological mechanisms
between osteoporosis and cardiovascular disease. F. Marini2 International Journal of Hypertension
and M. L. Brandi elegantly review the genetic aspects of
osteoporosis and touch on the shared mechanisms. The last
manuscript by G. Mertens oﬀers a unique perspective on
these issues by zooming out to take an evolutionary view. To
consider the underlying mechanisms of atherosclerosis, we
have to take a larger view without becoming lost in details of
the immediate.
We hope that this special issue is useful for your research
and is conducive to the incorporation of new concepts and
methods in your own laboratory.
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